PriceSensitive

Universal Biosensors (ASX:UBI) signs tech development deals

Health Care
ASX:UBI      MCAP $31.23M
13 April 2021 14:20 (AEST)

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.

The agreements with Deakin University’s Institute for Frontier Materials (DIFM) and Swinburne University of Technology will progress the commercialisation of the Tn Antigen biosensor, used for the detection, staging and monitoring of cancer, as well as the development of other biosensors using UBI’s electrochemical platform technology.

The Deakin University agreement contracts 50 per cent of the of Senior Fellow Dr Wren Green’s time and resources to UBI. The agreement is for a five-year term, for a fixed fee.

The Swinburne agreement contracts 80 per cent of Dr Saimon Moraes Silva’s time, also under a fixed fee, ending in February 2022. Dr Saimon will work under the supervision of Professor Simon Moulton of Swinburne’s School Software and Electrical Engineering and Iverson Health Innovation Research Institute.

Both agreements have fees payable by UBI, collectively coming under $300,000 per year.

“Using UBI’s platform technology we plan to deliver a cancer biosensor capable of identifying, staging and monitoring cancer from a finger prick of blood, using a portable hand held device,” said CEO of UBI John Sharman.

“The knowledge and resources of DIFM and Swinburne will help deliver this as well as fast track the development of other biosensors we are working on.”

Universal Biosensors shares are up 9.68 per cent, trading at 68 cents at 1:15 pm AEST.

Related News